This medical condition has either been superseded or has become inactive
Specific Conditions |
|
Indication for Ig Use |
|
Level of Evidence | Nil (Category 4b) |
Description and Diagnostic Criteria |
Recurrent and/or severe bacterial infections may arise from hypogammaglobulinaemia of diverse causes. Hypogammaglobulinaemia may arise from protein-losing states, malnutrition and medical immunosuppression. In most cases, successful management of the underlying condition will reverse the immunodeficiency, restoring immunocompetence. In some cases, recurrent or severe infection may arise from secondary immunodeficiency where the underlying cause cannot be reversed, or where there are unwanted effects of removing or reducing immunosuppressive therapy. New immunosuppressive regimens, such as monoclonal B-cell depletion with Rituximab or similar agents, do not generally induce hypogammaglobulinaemia at standard doses. However, repeated cycles of B-cell depletion in combination with other agents used to treat life-threatening immune-mediated diseases may increase rates of infection related to hypogammaglobulinaemia. |
Justification for Evidence Category |
|
Qualifying Criteria for Ig Therapy |
AND
AND
Antibiotic therapy may be indicated in addition to immunoglobulin therapy. |
Exclusion Criteria |
HIV in children. - see HIV in children
Transplantation-related immunomodulation (kidney transplantation). - see Kidney transplantation Transplantation-related immunomodulation (solid organ transplantation other than kidney). - see Solid organ transplantation (other than kidney) |
Review Criteria for Assessing the Effectiveness of Ig Use |
Initial review is required at six months by the Treating Medical Specialist and at least annually to assess the clinical benefit. Documentation of clinical effectiveness is necessary for continuation of Ig therapy.
Cessation of Ig therapy should be considered at least after each 12 months of therapy, extended as required to enable cessation of therapy in September/October, with repeat clinical and/or immunological evaluation before re-commencement of therapy. On review of an authorisation period Clinical effectiveness of Ig therapy may be demonstrated by:
AND
In principle, IVIg should be continued or renewed only if there is a demonstrated clinical benefit. Antibiotic therapy may be indicated in addition to immunoglobulin therapy. |
Dose |
Subcutaneous administration of immunoglobulins is a suitable alternative to IVIg in this condition, a suggested dose is 0.1 g/kg lean body mass every week, modified to achieve a serum IgG level of at least the lower limit of the age-specific serum IgG reference range. The aim should be to use the lowest dose possible that achieves the appropriate clinical outcome for each patient. Refer to the current product information sheet for further information. |
Bibliography |
---|
Orange, JS, Hossny, EM, Weiler, CR, et al 2006, ’Use of intravenous immunoglobulin in human disease: a review of primary evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology’, Journal of Allergy and Clinical Immunology, vol. 117, no. 4, pp. S525–53. |